| Trial ID: | L5319 |
| Source ID: | NCT02211742
|
| Associated Drug: |
Dapagliflozin
|
| Title: |
Dapagliflozin in Type 1 Diabetes
|
| Acronym: |
DapaT1DM
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Fasting Glucose|Glucose Excursion|Glycemic Control
|
| Interventions: |
DRUG: Dapagliflozin
|
| Outcome Measures: |
Primary: fasting glucose homeostasis, During hyperinsulinemic, euglycemic clamp studies, fasting glucose homeostasis will be determined for both, dapagliflozin and placebo., study visit, immediatly|postprandial glucose homeostasis, During euglycemic oral glucose tolerance clamp tests, postprandial glucose excursion will be determined and compared between dapagliflozin and placebo., study visit, immediatly |
|
| Sponsor/Collaborators: |
Sponsor: Medical University Innsbruck | Collaborators: Medical University of Graz|University of Bern
|
| Gender: |
MALE
|
| Age: |
ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
12
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2014-08
|
| Completion Date: |
2017-02-08
|
| Results First Posted: |
|
| Last Update Posted: |
2023-03-16
|
| Locations: |
Medical University Innsbruck, Department of Internal Medicine I, Innsbruck, Tirol, 6020, Austria
|
| URL: |
https://clinicaltrials.gov/show/NCT02211742
|
